<DOC>
	<DOCNO>NCT01046240</DOCNO>
	<brief_summary>This trial compare pharmacokinetics palonosetron administer subcutaneously intravenously .</brief_summary>
	<brief_title>Pharmacokinetic Evaluation Subcutaneous Versus Intravenous Palonosetron Cancer Treated With Chemotherapy</brief_title>
	<detailed_description>5-Hydroxitryptamine3 antagonist one mainstays antiemetic treatment administer either intravenously orally . Nevertheless sometimes neither administration route feasible , patient unable admit oral intake manage outpatient setting . Our objective evaluate bioavailability subcutaneous palonosetron.Patients receive platinum-based chemotherapy randomize receive palonosetron 3 mg either subcutaneously intravenously crossover manner two cycle . Blood urine sample collect cycle . Pharmacokinetics subcutaneous IV palonosetron prospectively compare .</detailed_description>
	<mesh_term>Palonosetron</mesh_term>
	<criteria>Cancer patient receive platinumbased chemotherapy adequate bone marrow , hepatic renal function Pregnancy Serious concomitant disease , invesgatorÂ´s criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>chemotherapy</keyword>
	<keyword>emesis</keyword>
	<keyword>palonosetron</keyword>
</DOC>